<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03958409</url>
  </required_header>
  <id_info>
    <org_study_id>2000022066</org_study_id>
    <nct_id>NCT03958409</nct_id>
  </id_info>
  <brief_title>Evaluation and Management of Metabolic Bone Disease in Kidney Transplant Recipients</brief_title>
  <official_title>Evaluation and Management of Metabolic Bone Disease in Kidney Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is a well-documented increased risk for disordered mineral bone homeostasis in Kidney&#xD;
      Transplant Recipients (KTRs) when compared to the general population, leading to a markedly&#xD;
      increased risk for fragility fractures and their associated morbidity and mortality. A more&#xD;
      uniform and rigorous evaluation of bone and mineral homeostasis,than is afforded to patients&#xD;
      under &quot;normal care&quot;, will result in better clinical outcomes in KTRs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim is to comprehensively characterize the mineral metabolism and skeletal phenotype in&#xD;
      kidney transplant recipients (KTRs) to being to identify risk factors for post-kidney&#xD;
      transplant mineral bone disease (PKT-MBD); and to evaluate whether treatment of abnormalities&#xD;
      in these parameters will improve skeletal health as quantified by bone mineral density (BMD),&#xD;
      bone turnover markers (rate of skeletal remodeling) and Osteoprobe (a direct index of bone&#xD;
      quality using reference point indentation technology.&#xD;
&#xD;
      Participants in the rigorous evaluation arm will be followed with a) Mineral metabolism:&#xD;
      blood calcium, phosphorus, parathyroid hormone (PTH), 25(OH) vitamin D; b) Bone turnover&#xD;
      markers: bone-specific alkaline phosphatase, cross-linked C-telopeptide of type I collagen&#xD;
      (CTx), and N-terminal propeptide of type I collagen (PINP); c)Bone Mineral Density using a&#xD;
      Dual energy x-ray absorptiometry which is the standard method by which bone mass is measured&#xD;
      clinically.&#xD;
&#xD;
      NOTE: The use of the Osteoprobe was discontinued on 9/5/19 due to safety concerns from the&#xD;
      FDA about the device in other trials/other sites.&#xD;
&#xD;
      The Control Cohort is essentially an historical control group who will have received standard&#xD;
      of care for the 18 months ending just prior to the enrollment of our Intervention Cohort. A&#xD;
      coincident Control Cohort will not be used because knowledge of the additional data to be&#xD;
      collected in the Control Cohort will undoubtedly influence their care by their attending&#xD;
      nephrologists and surgeons.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in bone turnover marker carboxy-terminal collagen crosslinks (CTx)</measure>
    <time_frame>18 months</time_frame>
    <description>In the intervention group changes in measures of mineral metabolism (serum calcium, phosphorus, PTH and 25 OH vitamin D levels), changes in bone turnover markers, BMD and bone quality markers will be compared to baseline results. The primary outcome variable will be the change in serum CTx from baseline. CTx is a marker of bone resorption and rates of resorption predict bone loss and fracture risk.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variance in bone loss</measure>
    <time_frame>18 months</time_frame>
    <description>the changes in PTH, CTx, Procollagen Type 1 N-Terminal Propeptide (P1NP), Trabecular Bone Score (TBS) and Bone Material Strength Index (BMSi) will be correlated with changes in bone mineral density (BMD) in a multiple regression model to determine their contributions to the variance in rates of bone loss. This will serve to inform our planned prospective study in terms of what measures to follow.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Skeletal Anomalies</condition>
  <condition>Kidney Transplant; Complications</condition>
  <arm_group>
    <arm_group_label>Rigorous evaluation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be evaluated for the rigorous evaluation received.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The participants will be evaluated for the standard of care received.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>measurements to evaluate metabolic bone disease</intervention_name>
    <description>The participants will be evaluated for a) Mineral metabolism: blood calcium, phosphorus, PTH, 25(OH) vitamin D; b) Bone turnover markers: bone-specific alkaline phosphatase, cross-linked C-telopeptide of type I collagen (CTx), and N-terminal propeptide of type I collagen (PINP); c) Bone Mineral Density using a Dual energy x-ray absorptiometry which is the standard method by which bone mass is measured clinically. The bone mass at the lumbar spine, wrist, hip and total body bone mass at 3, and 18 months.</description>
    <arm_group_label>Rigorous evaluation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>standard care</intervention_name>
    <description>Blood tests (Ca, Phos, PTH- mineral lab, 25OHVitD);Pregnancy Test (if applicable); dual energy X-ray absorptiometry (DXA); Bone Biopsy only if clinically indicated; treatment as clinically indicated.</description>
    <arm_group_label>Standard care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Kidney transplant subjects within the first 3 months after surgery (intervention&#xD;
             cohort) and 18 months after surgery (control cohort)&#xD;
&#xD;
          -  Age between 30 to 65 years old&#xD;
&#xD;
          -  Estimated glomerular filtration rate (GFR) &gt; 35 ml/min/1.73 m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major acute post-operatory complications (infection, urine leak, delayed graft&#xD;
             function)&#xD;
&#xD;
          -  Living related-donor KTRs&#xD;
&#xD;
          -  Estimated GFR ≤ 35 ml/min/1.73 m2&#xD;
&#xD;
          -  Significant skin disorder, bruising, local edema, skin infection or are being treated&#xD;
             with anticoagulants (such as warfarin, heparin, low molecular weight heparin or direct&#xD;
             thrombin inhibitors) or have known or acquired clotting disorders since the&#xD;
             OsteoProbe® procedure would be unsafe&#xD;
&#xD;
          -  Patients who do not plan to be followed at Yale New Haven for at least 18 months&#xD;
&#xD;
          -  Morbidly obese (BMI &gt;40)&#xD;
&#xD;
          -  History of gastroparesis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renata Belfort de Aguiar, Phd,MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Renata Belfort De Aguiar, PhD,MD</last_name>
    <phone>203-785-7474</phone>
    <email>renata.aguiar@yale.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale Transplantation Center/Yale-New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renata De Aguiar Belfort, PhD</last_name>
      <phone>203-785-7474</phone>
      <email>renata.aguiar@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Sanchez-Rangel, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Renata De Aguiar Belfort, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 16, 2019</study_first_submitted>
  <study_first_submitted_qc>May 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2019</study_first_posted>
  <last_update_submitted>November 5, 2020</last_update_submitted>
  <last_update_submitted_qc>November 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

